

Discovery of Lead Candidates for Parkinson's disease targeting novel TAS2R GPCR

Digmbio / Research center



NEUROSCIENCE	Lead
Product Type	Small molecule
Indication	Parkinson's disease
Target	Novel TAS2R GPCR
MoA(Mechanism of Action)	Novel TAS2R Agonist : Disease modifying treatment
Competitiveness	Our target is a new target molecule for the treatment of Neurodegeneration disease include PD. Since there is no efficacious PD drug, it is highly expected that the success of this project will lead to First in Class. The current hit compound DM3159 is effective in various PD assay systems, and is particularly competitive with Rasagline(MAO-B inhibitor, Disease modifying drug) in MPTP-induced PD animal models.
Development Stage	Lead
Route of Administration	Oral administration